Status:
COMPLETED
[S,S]-Reboxetine Dose-Range Finding Trial
Lead Sponsor:
Pfizer
Conditions:
Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the effectiveness of different doses of \[S,S\]-Reboxetine in the treatment of chronic pain following a shingles infection
Eligibility Criteria
Inclusion
- Patients must have pain present for more than 3 months after the healing of shingles skin rash
- Patients at screening must have a score \>/=40 mm on the pain visual analogue scale
Exclusion
- Patients with significant renal and hepatic impairment
- Patients with other severe pain, that may impair the self-assessment of the pain due to shingles
- Patients with clinically abnormal electrocardiogram
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
End Date :
February 1 2007
Estimated Enrollment :
280 Patients enrolled
Trial Details
Trial ID
NCT00288652
Start Date
March 1 2006
End Date
February 1 2007
Last Update
June 8 2011
Active Locations (79)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Huntsville, Alabama, United States
2
Pfizer Investigational Site
Chandler, Arizona, United States
3
Pfizer Investigational Site
Mesa, Arizona, United States
4
Pfizer Investigational Site
Phoenix, Arizona, United States